CPT 81002: Manual Urine Dipstick Chemical Analysis
Commercial payers pay $10 on average nationally for this procedure.
CPT code 81002 describes a manual urine reagent strip or tablet analysis where a laboratory analyst immerses or applies drops of a freshly collected urine specimen to a dipstick or reagent tablet, removes excess, allows the specified reaction time, and visually reads one or more analytes against a color chart; service type: manual urine chemical analysis (non-microscopic); typical site of service: clinical laboratory, point-of-care locations such as physician offices, urgent care, or outpatient clinics where rapid urine screening is performed.
For related coverage guidance, see recent payer policy updates: Vafseo (vadadustat) for anemia in CKD on dialysis, Metabolic Disorders - Cysteamine (Oral) Products for Individual and Family Plans, Kerendia (finerenone) — Coverage Criteria.
Customize your policy alerts
Sign up for cpt 81002 policy alerts
Get alerted when payer policies referencing 81002 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
National commercial rates for CPT 81002 center around BUCA’s average commercial benchmark of $10.4, with individual payer medians clustered both below and above that level. Blue Cross Blue Shield’s median sits higher at $15.8, while Aetna, Cigna, and UnitedHealth Group have medians near $3.5, $3.4, and $3.1 respectively. Cigna and UnitedHealth Group show relatively low upper tails (P90s at $5.7 and $5.9) compared with Blue Cross Blue Shield’s much higher P90 of $25.6, indicating significant variability at the top end for that payer.
Examining dispersion via the interquartile range (P75 minus P25) highlights differences in consistency: Blue Cross Blue Shield has the widest IQR at $11.5 (P75 $20.7 minus P25 $9.5), reflecting broad mid-range variability, while UnitedHealth Group is the tightest with an IQR of $1.5 (P75 $3.6 minus P25 $2.1). Aetna’s IQR is $3.5 and Cigna’s is $2.5; BUCA’s quartiles imply an IQR of $7.0 (P75 $13.9 minus P25 $6.4), positioning BUCA between the narrowest and widest payers.